In a welcome move, Intellia Therapeutics saw its Relative Strength Rating rise from 70 to 73 on Friday.
How To Invest In Stocks In Both Bull And Bear Markets
This proprietary rating tracks market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
History reveals that the best stocks tend to have an RS Rating of above 80 as they begin their largest price moves. See if Intellia Therapeutics can continue to show renewed price strength and clear that threshold.
Intellia Therapeutics is not currently showing a potential entry point. See if the stock goes on to build a chart pattern that could launch a new move.
The company posted 0% earnings growth last quarter. Sales rose -43%. The next quarterly numbers are expected on or around Jul. 31.
Intellia Therapeutics holds the No. 269 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
